Durham startup raises Series A to tackle undruggable proteins, including cancer baddie Myc, with generative AI
02 May 2023
PROTACs
The number of ways atoms can be arranged to create potential drugs is so large — 1063, by one estimate — that it exceeds the number of stars in the universe. It’s a number too vast for scientists to ever search through, at least on their own.
But a small startup spun out of Duke University hopes that a little help from AI could change that.
Ten63 Therapeutics raised $15.9 million in Series A financing led by Hatteras Venture Partners, the startup announced Tuesday. Co-founder and CEO Marcel Frenkel told
Endpoints News
that his company will explore possible structures for small molecule drugs “at a scale that has never been done before.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.